Head-To-Head Analysis: Neuralstem (NASDAQ:CUR) & Theravance Biopharma (TBPH)

Theravance Biopharma (NASDAQ: TBPH) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

86.6% of Theravance Biopharma shares are held by institutional investors. Comparatively, 7.0% of Neuralstem shares are held by institutional investors. 6.1% of Theravance Biopharma shares are held by company insiders. Comparatively, 19.3% of Neuralstem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Theravance Biopharma has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Profitability

This table compares Theravance Biopharma and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Theravance Biopharma -1,855.42% -136.86% -55.45%
Neuralstem -154,347.81% -148.94% -84.85%

Valuation & Earnings

This table compares Theravance Biopharma and Neuralstem’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $15.39 million 86.35 -$285.40 million ($5.45) -4.45
Neuralstem $20,000.00 1,249.88 -$21.07 million N/A N/A

Neuralstem has lower revenue, but higher earnings than Theravance Biopharma.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Theravance Biopharma and Neuralstem, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma 1 0 5 0 2.67
Neuralstem 0 0 0 0 N/A

Theravance Biopharma currently has a consensus price target of $43.33, suggesting a potential upside of 78.69%. Neuralstem has a consensus price target of $1.91, suggesting a potential upside of 15.76%. Given Theravance Biopharma’s higher probable upside, analysts clearly believe Theravance Biopharma is more favorable than Neuralstem.

Summary

Theravance Biopharma beats Neuralstem on 8 of the 11 factors compared between the two stocks.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

About Neuralstem

Neuralstem, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel and proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.